miR‑639 is associated with advanced cancer stages and promotes proliferation and migration of nasopharyngeal carcinoma Retraction in /10.3892/ol.2023.14209

Wang,Yun‑Hui; Yin,Yan‑Wei; Zhou,Han; Cao,Yuan‑Dong

doi:10.3892/ol.2018.9512

miR‑639 is associated with advanced cancer stages and promotes proliferation and migration of nasopharyngeal carcinoma

Retraction in: /10.3892/ol.2023.14209

Authors:
- Yun‑Hui Wang
- Yan‑Wei Yin
- Han Zhou
- Yuan‑Dong Cao
View Affiliations

Affiliations: Department of Ear, Nose and Throat, Linyi City People's Hospital, Linyi, Shandong 276000, P.R. China, Department of Oncology, Linyi City People's Hospital, Linyi, Shandong 276000, P.R. China, Department of Ear, Nose and Throat, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: September 27, 2018 https://doi.org/10.3892/ol.2018.9512
Pages: 6903-6909
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Early detection of nasopharyngeal carcinoma (NPC) is of vital importance for improving prognosis and survival rates. MicroRNA (miRNA) are a class of short and non‑coding RNA molecules that are capable of inhibiting the translation of mRNA of target genes. Previous studies have revealed that miRNA are involved in tumorigenesis and cancer development. The RNase‑resistance of circulating miRNA have made them valuable non‑invasive biomarkers, and has therefore drawn particular attention to their therapeutic potential. The aim of the present study was to investigate the expression of the previously uncharacterized miR‑639 in NPC. In a study population of 139 patients, higher expression of miR‑639 was associated with metastasis, more advanced cancer stages, and lower disease‑free survival rates. In vitro experiments involving transfection of human NPC C666‑1 and NPC/HK1 cell lines with miR‑639 mimics and antagomir indicated that overexpressing miR‑639 promoted cell proliferation and migration, suppression of miR‑639 inhibited proliferation and migration. The present study provides evidence that miR‑639 is differentially expressed in NPC tissues of varying cancer stages, and suggests that quantifying circulating miR‑639 may be of importance for non‑invasive diagnosis and prognostic evaluation, and may have potential therapeutic utility.

View Figures

View References

1	Mcdermott AL, Dutt SN and Watkinson JC: The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci. 26:82–92. 2001. View Article : Google Scholar : PubMed/NCBI
2	Huang TR, Zhang SW, Chen WQ, Deng W, Zhang CY, Zhou XJ and Zhai RH: Trends in nasopharyngeal carcinoma mortality in China, 1973–2005. Asian Pac J Cancer Prev. 13:2495–2502. 2012. View Article : Google Scholar : PubMed/NCBI
3	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
4	Wei WI and Sham JS: Nasopharyngeal carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
5	Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ and Ma J: How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 80:661–668. 2011. View Article : Google Scholar : PubMed/NCBI
6	Ma J, Mai HQ, Hong MH, Cui NJ, Lu TX, Lu LX, Mo HY and Min HQ: Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations? Int J Radiat Oncol Biol Phys. 50:1181–1189. 2001. View Article : Google Scholar : PubMed/NCBI
7	Giordano S and Columbano A: MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 57:840–847. 2013. View Article : Google Scholar : PubMed/NCBI
8	Gomes CC, de Sousa SF and Gomez RS: MicroRNAs: Small molecules with a potentially role in oral squamous cell carcinoma. Curr Pharm Des. 19:1285–1291. 2013. View Article : Google Scholar : PubMed/NCBI
9	Pasquinelli AE: MicroRNAs and their targets: Recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 13:271–282. 2012. View Article : Google Scholar : PubMed/NCBI
10	Fu HL, Wu DP, Wang XF, Wang JG, Jiao F, Song LL, Xie H, Wen XY, Shan HS, Du YX and Zhao YP: Altered miRNA expression is associated with differentiation, invasion, and metastasis of esophageal squamous cell carcinoma (ESCC) in patients from Huaian, China. Cell Biochem Biophys. 67:657–668. 2013. View Article : Google Scholar : PubMed/NCBI
11	Giles KM, Brown RA, Epis MR, Kalinowski FC and Leedman PJ: miRNA-7-5p inhibits melanoma cell migration and invasion. Biochem Biophys Res Commun. 430:706–710. 2013. View Article : Google Scholar : PubMed/NCBI
12	Salim H, Akbar NS, Zong D, Vaculova AH, Lewensohn R, Moshfegh A, Viktorsson K and Zhivotovsky B: miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer. 107:1361–1373. 2012. View Article : Google Scholar : PubMed/NCBI
13	Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A and Hu J: miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res. 29:1512010. View Article : Google Scholar : PubMed/NCBI
14	Li L, Qiu XG, Lv PW and Wang F: miR-639 promotes the proliferation and invasion of breast cancer cell in vitro. Cancer Cell Int. 14:392014. View Article : Google Scholar : PubMed/NCBI
15	Schickel R, Boyerinas B, Park SM and Peter ME: MicroRNAs: Key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 27:5959–5974. 2008. View Article : Google Scholar : PubMed/NCBI
16	Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, et al: Prognostic value of a microRNA signature in nasopharyngeal carcinoma: A microRNA expression analysis. Lancet Oncol. 13:633–641. 2012. View Article : Google Scholar : PubMed/NCBI
17	Lin Z, Sun L, Chen W, Liu B, Wang Y, Fan S, Li Y and Li J: miR-639 regulates transforming growth factor beta-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting FOXC1. Cancer Sci. 105:1288–1298. 2014. View Article : Google Scholar : PubMed/NCBI
18	Lei ST, Shen F, Chen JW, Feng JH, Cai WS, Shen L, Hu ZW and Xu B: miR-639 promoted cell proliferation and cell cycle in human thyroid cancer by suppressing CDKN1A expression. Biomed Pharmacother. 84:1834–1840. 2016. View Article : Google Scholar : PubMed/NCBI
19	Arantes L, de Carvalho AC, Melendez ME, Carvalho AL and Goloni-Bertollo EM: Methylation as a biomarker for head and neck cancer. Oral Oncol. 50:587–592. 2014. View Article : Google Scholar : PubMed/NCBI
20	Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 4:707–717. 2004. View Article : Google Scholar : PubMed/NCBI
21	Sebova K, Zmetakova I, Bella V, Kajo K, Stankovicova I, Kajabova V, Krivulcik T, Lasabova Z, Tomka M, Galbavy S and Fridrichova I: RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomark. 10:13–26. 2011. View Article : Google Scholar : PubMed/NCBI
22	Chang KP, Hao SP, Chang JH, Wu CC, Tsang NM, Lee YS, Hsu CL, Ueng SH, Liu SC, Liu YL, et al: Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes. Clin Cancer Res. 14:6979–6987. 2008. View Article : Google Scholar : PubMed/NCBI
23	Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O, et al: Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 51:810–824. 2005. View Article : Google Scholar : PubMed/NCBI
24	Bakir M, Millington KA, Soysal A, Deeks JJ, Efee S, Aslan Y, Dosanjh DP and Lalvani A: Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med. 149:777–786. 2008. View Article : Google Scholar : PubMed/NCBI
25	Gao M, Yin H and Fei ZW: Clinical application of microRNA in gastric cancer in Eastern Asian area. World J Gastroenterol. 19:2019–2027. 2013. View Article : Google Scholar : PubMed/NCBI
26	Liu X, Luo HN, Tian WD, Lu J, Li G, Wang L, Zhang B, Liang BJ, Peng XH, Lin SX, et al: Diagnostic and prognostic value of plasma microRNA deregulation in nasopharyngeal carcinoma. Cancer Biol Ther. 14:1133–1142. 2013. View Article : Google Scholar : PubMed/NCBI
27	Liu J, Valencia-Sanchez MA, Hannon GJ and Parker R: MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol. 7:719–723. 2005. View Article : Google Scholar : PubMed/NCBI
28	Ørom UA, Nielsen FC and Lund AH: MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 30:460–471. 2008. View Article : Google Scholar : PubMed/NCBI
29	O'Donnell KA, Wentzel EA, Zeller KI, Dang CV and Mendell JT: c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 435:839–843. 2005. View Article : Google Scholar : PubMed/NCBI
30	Büssing I, Slack FJ and Grosshans H: let-7 microRNAs in development, stem cells and cancer. Trends Mol Med. 14:400–409. 2008. View Article : Google Scholar : PubMed/NCBI
31	Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E and Tao J: Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 31:3002–3008. 2012. View Article : Google Scholar : PubMed/NCBI
32	Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M and Lund AH: p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 17:236–245. 2010. View Article : Google Scholar : PubMed/NCBI
33	Lei ST, Shen F, Chen JW, Feng JH, Cai WS, Shen L, Hu ZW and Xu B: miR-639 promoted cell proliferation and cell cycle in human thyroid cancer by suppressing CDKN1A expression. Biomed Pharmacother. 84:1834–1840. 2016. View Article : Google Scholar : PubMed/NCBI
34	Li L, Qiu XG, Lv PW and Wang F: miR-639 promotes the proliferation and invasion of breast cancer cell in vitro. Cancer Cell Int. 14:392014. View Article : Google Scholar : PubMed/NCBI
35	Endo H, Muramatsu T, Furuta M, Uzawa N, Pimkhaokham A, Amagasa T, Inazawa J and Kozaki K: Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer. Carcinogenesis. 34:560–569. 2013. View Article : Google Scholar : PubMed/NCBI
36	Wu S, Huang S, Ding J, Zhao Y, Liang L, Liu T, Zhan R and He X: Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3′ untranslated region. Oncogene. 29:2302–2308. 2010. View Article : Google Scholar : PubMed/NCBI
37	Ragusa M, Caltabiano R, Russo A, Puzzo L, Avitabile T, Longo A, Toro MD, Di Pietro C, Purrello M and Reibaldi M: MicroRNAs in vitreus humor from patients with ocular diseases. Mol Vis. 19:430–440. 2013.PubMed/NCBI
38	Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, Theodorescu D, Ostenfeld MS, Hartmann A, Borre M, Ørntoft TF and Dyrskjøt L: miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics. 5:402012. View Article : Google Scholar : PubMed/NCBI
39	Sandip KM: Unravelling the mechanism of ERR beta behind its role as a tumor suppressor and contribution of specific miRNAs and co-regulators in breast cancer cell lines. J Cancer Sci Ther. 6:102014.
40	Smart CE, Amiri Askarian ME, Wronski A, Dinger ME, Crawford J, Ovchinnikov DA, Vargas AC, Reid L, Simpson PT, Song S, et al: Expression and function of the protein tyrosine phosphatase receptor J (PTPRJ) in normal mammary epithelial cells and breast tumors. PLoS One. 7:e407422012. View Article : Google Scholar : PubMed/NCBI
41	Spring K, Fournier P, Lapointe L, Chabot C, Roussy J, Pommey S, Stagg J and Royal I: The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis. Oncogene. 34:5536–5547. 2015. View Article : Google Scholar : PubMed/NCBI
42	Kakkoura MG, Demetriou CA, Loizidou MA, Loucaides G, Neophytou I, Malas S, Kyriacou K and Hadjisavvas A: MnSOD and CAT polymorphisms modulate the effect of the Mediterranean diet on breast cancer risk among Greek-Cypriot women. Eur J Nutr. 55:1535–1544. 2016. View Article : Google Scholar : PubMed/NCBI
43	Ralph DA, Zhao LP, Aston CE, Manjeshwar S, Pugh TW, DeFreese DC, Gramling BA, Shimasaki CD and Jupe ER: Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk. Cancer. 109:1940–1948. 2007. View Article : Google Scholar : PubMed/NCBI
44	Wu S, Huang S, Ding J, Zhao Y, Liang L, Liu T, Zhan R and He X: Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3′untranslated region. Oncogene. 29:2302–2308. 2010. View Article : Google Scholar : PubMed/NCBI